- Home
- CGTX vs ASRT Comparison
CGTX vs ASRT Comparison
Compare CGTX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGTX | ASRT |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 76.0M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | CGTX | ASRT |
|---|---|---|
| Price | $1.08 | $11.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.33 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 595.0K | 22.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.51 |
| 52 Week High | $3.83 | $12.95 |
Technical Indicators
Market Signals| Indicator | CGTX | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 54.17 |
| Support Level | $1.00 | $11.05 |
| Resistance Level | $1.19 | $12.45 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 36.11 | 53.85 |
Price Performance
Historical ComparisonAbout CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.